Other languages CureVac N.V.

Equities

CVAC

NL0015436031

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
3.89 ^USD	+3.18%		+5.42%	-7.60%

May. 28	CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate	MT
May. 28	CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza, Development in Collaboration with GSK	May. 29
CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate	May. 28
CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK	May. 28
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK	May. 28
CureVac N : Proxycard AGM 2024	May. 24
CureVac N : Dutch Statutory Board Report and Financial Statements of CureVac N.V. 2023	May. 24
CureVac N : Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) - Form 6-K	May. 23
CureVac N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 23
CUREVAC : Significant cash drain in the Q1	May. 23
CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update	May. 23
Health Care Up as Vaccine Makers Gain - Health Care Roundup	May. 22
News Highlights : Top Company News of the Day - Wednesday at 5 PM ET	May. 22
CUREVAC : A missed opportunity	May. 02
UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating	Apr. 26
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza Development in Collaboration with GSK	Apr. 25
Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4	Apr. 25
CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25
CureVac Begins Early Stage Portion of Investigational Vaccine Trial	Apr. 24
CureVac Hires New Chief Business Officer	Apr. 24
CureVac, GSK Launch Phase 1/2 Trial of Bird Flu Vaccine Candidate	Apr. 24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

CUREVAC : Significant cash drain in the Q1

May 23, 2024 at 03:49 pm EDT